Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
馬里蘭州銀泉，2024年5月2日（環球新聞專線）——開創藥物洗脫生物矩陣產品的公司Elutia Inc.（納斯達克股票代碼：ELUT）（“Elutia”）今天宣佈，將在2024年5月9日星期四收盤後發佈其2024年第一季度財務業績。公司管理團隊成員將在當天美國東部時間下午 4:30 /太平洋時間下午 1:30 開始主持電話會議和網絡直播。
The conference call can be accessed using the following information:
可以使用以下信息訪問電話會議：
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13746000
網絡直播：點擊這裏
美國投資者：877-407-8029
國際投資者：201-689-8029
會議 ID：13746000
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the "Investors" section of the Elutia website at
請在預定開始時間前大約 10 分鐘登錄。該活動的直播和存檔網絡直播將在Elutia網站的 “投資者” 部分播出，網址爲
About Elutia
關於 Elutia
Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit .
Elutia 開發和商業化生物製劑，以改善醫療器械與需要它們的患者之間的兼容性。隨着越來越多的人口需要植入式技術，Elutia的使命是實現醫學人性化，使患者能夠毫不妥協地茁壯成長。欲了解更多信息，請訪問。
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
投資者：
馬特·斯坦伯格
FINN 合作伙伴
matt.steinberg@finnpartners.com